Dysregulation of the cyclin D1/CDK4 pathway occurs in a majority of melanomas and increased cyclin D1/CDK4 activity (e.g. loss of p16Ink4A or Fbxo4) cooperates with BrafV600E to drive melanoma. Here, CDK4 is linked to melanoma.